New Findings in Breast CancerApril 19, 2012
"It is fashionable to think of breast cancer as a disease that can be treated if cancer stem cells are killed off, but we are reporting a sub-population of cancer cells that have no obvious stem cell properties and yet can be tumorigenic and highly aggressive," Bissell says. "The existence of these additional sub-populations of tumorigenic cells tells us that the entire tumor needs to be eradicated, not just one sub-population of basal-like cells."
Bissell is a leading authority on breast cancer and a Distinguished Scientist with Berkeley Lab's Life Sciences Division. Petersen is a professor of Tissue Morphogenesis and Differentiation for CU's Cellular and Molecular Medicine department and a principal investigator for the Danish Stem Cell Center. They are the corresponding authors of a paper in the Proceedings of the National Academy of Sciences that describes this work. The paper is titled "Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity." Other co-authors were Jiyoung Kim, René Villadsen, Therese Sørlie, Louise Fogh, Signe Grønlund, Agla Fridriksdottir, Irene Kuhn, Fritz Rank, Vera Timmermans Wielenga, Hiroko Solvang, Paul Edwards, Anne-Lise Børresen-Dale and Lone Rønnov-Jessen.
"Our findings were a surprise to us as we had hypothesized the opposite scenario," Petersen says. "We wanted to learn more about possible tumor suppressive properties so we set out to characterize the bulk of the tumor, which we assumed would not be tumor-initiating."
Most breast cancers originate in the milk ducts and lobules, which consist of luminal cells surrounded by basal cells, and the two most frequent subtypes of human breast cancer cells are named luminal-like and basal-like after their resemblance to the two major lineages in the normal human breast. For the past several years, it has been widely believed that basal-like cells with the undifferentiated qualities of stem cells were the source of invasive tumors. However, since a majority of breast cancers exhibit luminal cell differentiation, the Petersen-Bissell collaboration investigated whether luminal-like differentiated cells within a basal-like cell hierarchy could also become tumorigenic, or must these luminal-like cells acquire basal-like traits to become malignant.
"We applied some rare and mutually exclusive lineage markers to isolate subsets of luminal-like and basal-like breast cancer cells, which enabled us to do single cell cloning with a reasonable success rate," Petersen says. "We enriched for populations with or without prominent basal-like traits from individual tumors, and from single cell cloning of cell lines and recovered cells with a luminal-like phenotype."
What they discovered was that luminal-like cells without specific basal-like traits were fully capable of initiating tumors in laboratory test mice; in fact, the tumors generated by luminal-like cells were larger than those from basal-like cells. In addition, when tested in an invasion assay, these phenotypically pure luminal-like cells were more invasive than the basal-like cells.
"Our findings demonstrate that basal-like cells, as defined currently, are not a requirement for breast tumor aggressiveness and that within a single tumor there are multiple cells with tumorigenic potential," Bissell says. "This casts doubt on the current hypothesis of hierarchical or differentiative loss of tumorigenicity."
The marker used by the Petersen-Bissell collaboration to isolate the luminal-like cancer cells was milk mucin (MM), one of the glycans, the sugar molecules that are ubiquitous to cell surfaces and central to cellular signaling. Basal-like cancer cells were marked with the protein CD271. The MM glycan was detected by the antibody M18. The CD271 marker was detected by the ME20.4 antibody.
In their investigation, the collaborators found that the ability of the luminal-like breast cancer cells to form large invasive tumors depended on the expression of the glycoprotein gene GCNT1, which in turn is required for the MM glycan to be detected by the M18 antibody. The collaborators believe this finding might be of potential clinical importance for breast cancer as co-author Kuhn, a member of Bissell's research group, explains.
"There has been an increasing appreciation that glycans play an important role in malignant behavior and our work shows that inhibiting the activity of GCNT1 could prevent the invasive behavior of the aggressive luminal-like cancer cells if they express the MM epitope," she says.
Although Petersen emphasizes that any clinical implications of this work remains speculative at this time, the finding that multiple types of cells in breast cancers are capable of initiating invasive tumors, he says, could hold implications for future personalized medicine.
"While new avenues in breast cancer targeting have been strongly influenced by the concepts of tumor subtypes and cancer stem cells, we believe our data and recent data from other laboratories opens the possibility of targeting individual stages of differentiation of breast cancer cells within a tumor," Petersen says. "In that way personalized medicine in the future could rely on a cellular-composition-profile with each cellular component accounted for in the treatment design."
This research was supported by grants from the Danish Cancer Society, the Novo Nordisk Foundation, and the Danish Council for Strategic Research, and in part the National Cancer Institute, the breast cancer program of the U.S. Department of Defense, and the U.S. Department of Energy's Office of Science
Lawrence Berkeley National Laboratory
Related Breast Cancer Current Events and Breast Cancer News Articles
Chitosan-coated, chemotherapy-packed nanoparticles may target cancer stem cells
Nanoparticles packed with a clinically used chemotherapy drug and coated with an oligosaccharide derived from the carapace of crustaceans might effectively target and kill cancer stem-like cells, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Atomic force microscope advance leads to new breast cancer research
Researchers who developed a high-speed form of atomic force microscopy have shown how to image the physical properties of live breast cancer cells, for the first time revealing details about how deactivation of a key protein may lead to metastasis.
How removing a protein slows blood vessel growth in tumors
Scientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumours which have spread to the brain, a common location which breast cancer can spread to.
Targeting telomeres, the timekeepers of cells, could improve chemotherapy
Telomeres, specialized ends of our chromosomes that dictate how long cells can continue to duplicate themselves, have long been studied for their links to the aging process and cancer.
Eavesdropping on the body: New device tracks chemical signals within cells
Biomedical engineers at the University of Toronto have invented a new device that more quickly and accurately "listens in" on the chemical messages that tell our cells how to multiply.
Latina women undergoing chemotherapy for breast cancer need more stress management tools
Cancer is the most common cause of death among Latinos. It is estimated that one out of every three Latina women will be diagnosed with cancer during her lifetime.
Stress hormones could undermine breast cancer therapy
Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.
Percentages of patients undergoing breast-conserving therapy increases
The percentage of patients with early-stage breast cancer undergoing breast-conserving therapy increased from 54.3 percent in 1998 to 60.1 percent in 2011, although nonclinical factors including socioeconomic demographics, insurance and the distance patients must travel to treatment facilities persist as key barriers to the treatment, according to a report published online by JAMA Surgery.
Breast-conserving therapy for early-stage cancers has increased, though access an issue
The first comprehensive national review of breast-conserving therapy (BCT) shows that over the last 13 years rates of this treatment modality for early-stage breast cancer have increased at a steady pace.
Tests to gauge genetic risks for prostate cancer now are feasible
Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.
More Breast Cancer Current Events and Breast Cancer News Articles